Neal K. Lakdawala, MD, Anjali Tiku Owens, MD - Loosening the Grip of Hypertrophic Cardiomyopathy: Updated Strategies for Timely Diagnosis and Disease-Modifying Treatment

Go online to PeerView.com/GYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and has a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. The FDA has recently approved a noninvasive, first-in-class cardiac myosin inhibitor specifically indicated for the treatment of HCM—meaning timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment. In this activity, based on a recent live symposium, expert panelists present practical skills and guidance to accurately diagnose HCM and apply recent treatment advances to patients with various clinical presentations of HCM. They begin by sharing the rationale for maintaining a high index of suspicion for HCM and review diagnostic strategies. The Clinical Consults portion of this activity features case examples to demonstrate current practices in diagnosis and offer practical guidance for treating patients—focusing on personalized care with new and emerging therapeutic options. Concluding with an engaging Q&A, this activity is for anyone involved in the care of patients with HCM interested in loosening the grip of this increasingly treatable disease. Upon completion of this activity, participants should be better able to: Suspect the presence of HCM based on clinical symptoms, pathologic features, and/or family history; Differentially diagnose patients suspected of having HCM consistent with current guidance to promote early diagnosis and timely treatment; and Individualize treatment for patients with HCM based on the efficacy, safety, and potential ability of the therapeutic strategy to address the underlying disease pathophysiology.